Skip to Main Content

Paper Details

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer.
J Clin Oncol
15
2023
ER, HER-2, PR, Patients, RD, TNBC, Triple-Negative Breast Cancer, Triple-negative breast cancer, breast cancer, estrogen, estrogen receptor, human, human epidermal growth factor receptor 2, patients, progesterone, progesterone receptor
Author NameAffiliation
Kenneth R HessThe University of Texas M.D. Anderson Cancer Center, University of Munster, Marseille Public Hospital System, Marseille and Breast Cancer Unit and Translational Research Unit UPRES03535, Institut Gustave Roussy
Kenneth R HessThe University of Texas M.D. Anderson Cancer Center, University of Munster, Marseille Public Hospital System, Marseille and Breast Cancer Unit and Translational Research Unit UPRES03535, Institut Gustave Roussy
William F SymmansThe University of Texas M.D. Anderson Cancer Center, University of Munster, Marseille Public Hospital System, Marseille and Breast Cancer Unit and Translational Research Unit UPRES03535, Institut Gustave Roussy
Massimo CristofanilliThe University of Texas M.D. Anderson Cancer Center, University of Munster, Marseille Public Hospital System, Marseille and Breast Cancer Unit and Translational Research Unit UPRES03535, Institut Gustave Roussy
Gabriel N HortobagyiThe University of Texas M.D. Anderson Cancer Center, University of Munster, Marseille Public Hospital System, Marseille and Breast Cancer Unit and Translational Research Unit UPRES03535, Institut Gustave Roussy
Lajos PusztaiThe University of Texas M.D. Anderson Cancer Center, University of Munster, Marseille Public Hospital System, Marseille and Breast Cancer Unit and Translational Research Unit UPRES03535, Institut Gustave Roussy
  • 1 - 6

Datasets

Release 1.2